Modification of cell cycle and viability of TLX5 lymphoma in vitro by sulfoxide-ruthenium compounds and cisplatin detected by flow cytometry

Chemico-Biological Interactions

Volumn 113, Issue 1, 1998, Pages 51-64

  Capozzi, Ilaria ^a   Clerici, Katiuscia ^a   Cocchietto, Moreno ^a   Salerno, Giovanni ^a   Bergamo, Alberta ^a   Sava, Gianni ^a  

^a Callerio Foundation   (Italy)

Author keywords

Cisplatin; Flow cytometry; In vitro; Ruthenium; Tumour

Indexed keywords

ACRIDINE ORANGE; BROXURIDINE; CISPLATIN; DNA FRAGMENT; DOXORUBICIN; PROPIDIUM IODIDE; RHODAMINE B; RUTHENIUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CELL CYCLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LYMPHOMA; MOUSE; NONHUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS; BROMODEOXYURIDINE; CELL CYCLE; CELL SURVIVAL; CISPLATIN; DIMETHYL SULFOXIDE; DNA, NEOPLASM; DOXORUBICIN; FLOW CYTOMETRY; LUNG NEOPLASMS; LYMPHOMA; MICE; MICE, INBRED CBA; ORGANOMETALLIC COMPOUNDS; RUTHENIUM; TUMOR CELLS, CULTURED;

EID: 0031812413     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(98)00022-2     Document Type: Article

References (25)

1. 4DMSO)Im] in the mouse. Clin. Exp. Metastasis. 12:1994;93-100.
2. 4DMSO)Im], a metal complex of ruthenium with antimetastatic properties. Clin. Exp. Metastasis. 10:1992;273-280.
3. 4DMSO)Im]2DMSO. Drugs Future. 18:1993;894-900.
4. 4DMSO)Im]. Selective inhibition of spontaneous lung metastases by the ruthenium complex. Drug Invest. 8:1994;150-161.
5. Giraldi T., Sava G. Selective antimetastatic drugs review). Anticancer Res. 1:1980;163-174.
6. Giraldi T., Sava G. Malignancy and tumour proteinases: effects of proteinase inhibitors. Turk V., Vitale L. Proteinases and their Inhibitors. Structure, Function and Applied Aspects. 1981;45-56 Pergamon, Oxford.
7. Giraldi T., Sava G., Cuman R., Nisi C., Lassiani L. Selectivity of the antimetastatic and cytotoxic effects of l-p-3,3-dimethyl-l-triazeno)benzoic acid potassium salt, ±)-1,2-didioxopiperazin-l-yl)propane and cyclophosphamide in mice bearing Lewis lung carcinoma. Cancer Res. 41:1981;2524-2528.
8. Honn K.V. Inhibition of tumour cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system. Clin. Exp. Metastasis. 1:1983;103-114.
9. Sava G., Giraldi T., Lassiani L., Nisi C. Mechanism of the antimetastatic action of dimethyltriazenes. Cancer Treat. Rep. 63:1979;93-98.
10. Sava G., Perissin L., Zorzet S., Piccini P., Giraldi T. Antimetastatic action of the prostacyclin analog Iloprost in the mouse. Clin. Exp. Metastasis. 7:1989;671-678.
11. Sava G., Pacor S., Bergamo A., Cocchietto M., Mestroni G., Alessio E. Effects of ruthenium complexes on experimental tumours: irrelevance of cytotoxicity for metastasis inhibition. Chem.-Biol. Interact. 95:1995;109-126.
12. Sava G., Capozzi I., Bergamo A., Gagliardi R., Cocchietto M., Masiero L., Onisto M., Alessio E., Mestroni G., Garbisa S. Down regulation of tumor gelatinase/inhibitor balance and preservation of tumor endothelium by an antimetastatic ruthenium complex. Int. J. Cancer. 68:1996;60-66.
13. Mestroni G., Alessio E., Sava G., Pacor S., Coluccia M., Boccarelli A. Water soluble rutheniumIII)-dimethyl sulfoxide complexes: chemical behaviour and pharmacological properties. Metal Based Drugs. 1:1993;41-63.
14. 3. Inorg. Chim. Acta. 203:1993;205-217.
15. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J.T., Bokesch H., Kenney S., Boyd M.R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82:1990;1107-1112.
16. Darzynkiewicz Z. Differential staining of DNA and RNA in intact cells and isolated nuclei with acridine orange. Darzynkiewicz Z., Crissman H.A. Flow Cytometry. 1990;285-299 Academic Press, San Diego.
17. Tamura H., Arai T., Nagase M., Ichinose N. Determination of ruthenium in biological tissue by graphite furnace AAS after decomposition of the sample by Tetramethylammonium hydroxide. Bunseki Kagaku. 41:1992;T13-T18.
18. Mestroni G., Alessio E., Sava G., Pacor S., Coluccia M. The development of tumor-inhibiting ruthenium dimethylsulfoxide complexes. Keppler B.K. Metal Complexes in Cancer Chemotherapy. 1983;157-185 VCH Verlagegeshellschaft, Weinheim.
19. Sava G., Zorzet S., Giraldi T., Mestroni G., Zassinovich G. Antineoplastic activity and toxicity of an organometallic complex of rutheniumII) in comparison with cisPDD in mice bearing solid malignant neoplasms. Eur. J. Cancer Clin. Oncol. 20:1984;841-847.
20. Giraldi T., Sava G., Bertoli G., Mestroni G., Zassinovich G. Antitumor action of two rhodium and ruthenium complexes in comparison with cis-diamminedichloro platinumII). Cancer Res. 37:1977;2662-2666.
21. MacDougall J.R., Matrisian L.M. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev. 14:1995;351-362.
22. Radinsky R. Modulation of tumour cell gene expression and phenotype by the organ-specific metastatic environment. Cancer Metastasis Rev. 14:1995;323-338.
23. 4DMSO)Im] and ruthenium uptake by tumour cells. Anti-Cancer Drugs. 7:1996;697-702.
24. Sledge G.W. Jr., Qulali M., Goulet R., Bone E.A., Fife R. Effect of matrix metalloproteinase inhibitor Batimastat on breast cancer regrowth and metastasis in athymic mice. J. Natl. Cancer Inst. 87:1995;1546-1550.
25. Schneider M.R., Schirner M., Lichtner R.B., Graf H. Antimetastatic action of the prostacyclin analogue cicaprost in experimental mammary tumors. Breast Cancer Res. Treat. 38:1996;133-141.